Asahi Kasei Pharma – Product Pipeline Review – 2012 - Global Market Direct's pharmaceuticals report, "Asahi Kasei Pharma - Product Pipeline Review - 2012" provides data on the Asahi Kasei Pharma's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from our proprietary databases, Asahi Kasei Pharma's corporate website, SEC filings, investor presentations and featured press releases, both from Asahi Kasei Pharma and industry-specific third party sources, put together by our team.
Scope
- Asahi Kasei Pharma - Brief Asahi Kasei Pharma overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Asahi Kasei Pharma human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Asahi Kasei Pharma with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Asahi Kasei Pharma's pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Asahi Kasei Pharma's strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Asahi Kasei Pharma in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Asahi Kasei Pharma's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Asahi Kasei Pharma.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Asahi Kasei Pharma and identify potential opportunities in those areas.
Table of Contents
Table of Contents
List of Tables
List of Figures
Asahi Kasei Pharma Snapshot
Asahi Kasei Pharma Overview
Key Information
Key Facts
Asahi Kasei Pharma – Research and Development Overview
Key Therapeutic Areas
Asahi Kasei Pharma – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Asahi Kasei Pharma – Pipeline Products Glance
Asahi Kasei Pharma – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Asahi Kasei Pharma Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Asahi Kasei Pharma – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Asahi Kasei Pharma – Drug Profiles
AK-106
Product Description
Mechanism of Action
R&D Progress
ATS-8535
Product Description
Mechanism of Action
R&D Progress
ATS-907
Product Description
Mechanism of Action
R&D Progress
famciclovir
Product Description
Mechanism of Action
R&D Progress
fasudil
Product Description
Mechanism of Action
R&D Progress
LT-0101
Product Description
Mechanism of Action
R&D Progress
pentosan polysulfate sodium
Product Description
Mechanism of Action
R&D Progress
thrombomodulin alfa
Product Description
Mechanism of Action
R&D Progress
Asahi Kasei Pharma – Pipeline Products by Route of Administration
Asahi Kasei Pharma – Pipeline Products By Mechanism of Action
Asahi Kasei Pharma – Recent Pipeline Updates
Asahi Kasei Pharma - Dormant Projects
Asahi Kasei Pharma – Locations And Subsidiaries
Head Office
Financial Deals Landscape
Asahi Kasei Pharma, Deals Summary
Asahi Kasei Pharma, Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Artisan Pharma Secures $22 Million In Series B Financing
Partnerships
Asahi Kasei Pharma Enters Into Co-Promotion Agreement With Eisai China
Licensing Agreements
Asahi Kasei Pharma Enters Into Licensing Agreement With CoTherix
Zosano Pharma Enters Into Licensing Agreement With Asahi Kasei Pharma
Auxilium Pharma Enters Into Licensing Agreement With Asahi Kasei For XIAFLEX
Asahi Kasei Pharma Enters Into Licensing Agreement With Novartis Pharma
Asahi Kasei Enters Into Licensing Agreement With Altheos
Dong-A Signs License Agreement With Asahi Kasei Pharma
ReqMed, Bene PharmaChem Enters Into Licensing Agreement With Asahi Kasei Pharma
Asahi Kasei Pharma Enters Into Licensing Agreement With Eisai Korea
Artisan Pharma Enters Into Licensing Agreement With Asahi Kasei Pharma
Asset Transactions
CooperVision Acquires Operations Of Contact Lens Business From Asahi kasei Aime
Acquisition
Asahi Kasei Pharma Acquires Remaining Stake In Artisan Pharma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Asahi Kasei Pharma, Key Information
Asahi Kasei Pharma, Key Facts
Asahi Kasei Pharma – Pipeline by Indication, 2012
Asahi Kasei Pharma – Pipeline by Stage of Development, 2012
Asahi Kasei Pharma – Monotherapy Products in Pipeline, 2012
Asahi Kasei Pharma – Filed, 2012
Asahi Kasei Pharma – Phase III, 2012
Asahi Kasei Pharma – Phase II, 2012
Asahi Kasei Pharma – Pre-Clinical, 2012
Asahi Kasei Pharma – Discovery, 2012
Asahi Kasei Pharma – Pipeline By Route of Administration, 2012
Asahi Kasei Pharma – Pipeline Products By Mechanism of Action, 2012
Asahi Kasei Pharma – Recent Pipeline Updates, 2012
Asahi Kasei Pharma - Dormant Developmental Projects,2012
Asahi Kasei Pharma, Deals Summary
Artisan Pharma Secures $22 Million In Series B Financing
Asahi Kasei Pharma Enters Into Co-Promotion Agreement With Eisai China
Asahi Kasei Pharma Enters Into Licensing Agreement With CoTherix
Zosano Pharma Enters Into Licensing Agreement With Asahi Kasei Pharma
Auxilium Pharma Enters Into Licensing Agreement With Asahi Kasei For XIAFLEX
Asahi Kasei Pharma Enters Into Licensing Agreement With Novartis Pharma
Asahi Kasei Enters Into Licensing Agreement With Altheos
Dong-A Signs License Agreement With Asahi Kasei Pharma
ReqMed, Bene PharmaChem Enters Into Licensing Agreement With Asahi Kasei Pharma
Asahi Kasei Pharma Enters Into Licensing Agreement With Eisai Korea
Artisan Pharma Enters Into Licensing Agreement With Asahi Kasei Pharma
CooperVision Acquires Operations Of Contact Lens Business From Asahi kasei Aime
Asahi Kasei Pharma Acquires Remaining Stake In Artisan Pharma
List of Figures
Asahi Kasei Pharma – Pipeline by Indication, 2012
Asahi Kasei Pharma – Pipeline by Stage of Development, 2012
Asahi Kasei Pharma – Monotherapy Products in Pipeline, 2012
Asahi Kasei Pharma – Pipeline By Route of Administration, 2012
Asahi Kasei Pharma - Pipeline Products By Mechanism of Action, 2012 27
